ADAP Advocacy has released a new infographic as part of its ongoing 340B Project, drawing attention to the troubling disconnect between the 340B Drug Pricing Program's explosive growth and its original mission of improving patient care. The infographic, available for download via a dedicated link, reinforces the central message of the policy paper and commercial released earlier this year under the same title: "340B PROGRAM: The Glue That Should Hold Our Healthcare System Together." At a time when 340B drug purchases exceeded $100 billion in 2025 across more than 42,000 covered entities and over 32,000 pharmacies, the program's expansion has not translated into proportional benefits for the vulnerable patients it was designed to serve.
Congress created the 340B Drug Pricing Program to extend federal resources and improve patient care, and the Affordable Care Act added requirements for hospitals to provide free care and financial aid to poor patients, known as charity care. However, charity care continues to decline year after year, even as the program balloons. The new infographic connects these dots, illustrating how the program's unfettered growth is failing to deliver on its promise. It highlights hospitals' declining charity care, rising healthcare executive compensation, and exploding patient medical debt, among other issues. These trends suggest that the 340B program, intended to be a lifeline for vulnerable populations, may instead be enriching large hospital systems at the expense of the patients it was meant to help.
The implications are significant for policymakers, healthcare providers, and patients alike. With 340B purchases surpassing $100 billion, the program represents a massive flow of federal resources. If charity care is shrinking while executive pay and patient debt rise, the program's integrity and effectiveness are called into question. This infographic continues ADAP Advocacy's '340B Too Big To Fail' national advocacy campaign, which argues that the program is too entrenched to dismantle but must be reformed to ensure it serves its intended purpose. The campaign and this latest infographic amplify calls for greater transparency and accountability in how 340B savings are used.
For stakeholders, the message is clear: the 340B program is at a crossroads. Without meaningful reform, the gap between the program's stated goals and its actual outcomes will continue to widen. ADAP Advocacy's work underscores the urgent need to realign the 340B program with its original mission of expanding access to care for underserved populations. As the debate over healthcare costs and drug pricing intensifies, the evidence presented in this infographic adds a critical perspective to the conversation, urging a reevaluation of how the program's benefits are distributed.
